Overview

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Status:
Not yet recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

Triple negative breast cancer (TNBC), characterized by estrogen receptor, progesterone receptor and HER2 negative, accounts for 10-20% of all breast cancers and usually occurs in young women. It is an aggressive and worst prognosis breast cancer subtype, which urgently requires effective treatment.The pathological complete response (pCR) of neoadjuvant therapy is associated with disease-free survival (DFS) and overall survival (OS) of breast cancer. The correlation between pathological response and long-term survival in patients with early-stage breast cancer is the strongest among patients with triple-negative breast cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Henan Cancer Hospital

Treatments:

Albumin-Bound Paclitaxel
Epirubicin
Paclitaxel